Advanced

Role of biochemical markers in the management of osteoporosis

Ebeling, P and Åkesson, Kristina LU (2001) In Baillière's Best Practice & Research: Clinical Rheumatology 15(3). p.385-400
Abstract
Several serum and urine biochemical markers of bone resorption and formation have been developed. Biochemical bone markers have been used as intermediate end-points in all major studies of anti-osteoporotic therapies. Bone resorption markers, in particular, may add an independent, predictive value to the assessment of bone loss and fracture risk. There are also potential advantages in monitoring anti-osteoporotic treatment in the short-term in addition to bone densitometry, to rapidly identify non-responders to therapy, or non-compliance. Despite these recent advances, until now bone markers have simply been very useful research tools, with their clinical utility being limited by intra-individual and diurnal variability. However, the... (More)
Several serum and urine biochemical markers of bone resorption and formation have been developed. Biochemical bone markers have been used as intermediate end-points in all major studies of anti-osteoporotic therapies. Bone resorption markers, in particular, may add an independent, predictive value to the assessment of bone loss and fracture risk. There are also potential advantages in monitoring anti-osteoporotic treatment in the short-term in addition to bone densitometry, to rapidly identify non-responders to therapy, or non-compliance. Despite these recent advances, until now bone markers have simply been very useful research tools, with their clinical utility being limited by intra-individual and diurnal variability. However, the probability of the true bone mineral density response to hormone replacement therapy for the individual patient may be predicted using algorithms based on a spectrum of cut-off bone marker levels with varying false positive and negative rates. Thus, the transition of biochemical bone markers into everyday clinical practice may be rapidly approaching. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biochemical bone markers, fracture risk, therapy, bone density, non-responders
in
Baillière's Best Practice & Research: Clinical Rheumatology
volume
15
issue
3
pages
385 - 400
publisher
Baillière Tindall
external identifiers
  • scopus:0034879092
ISSN
1532-1770
DOI
10.1053/berh.2001.0156
language
English
LU publication?
yes
id
4f2db317-ae5c-4a36-a172-13348bc0bfc9 (old id 1136739)
alternative location
http://europepmc.org/abstract/MED/11485336
date added to LUP
2016-01-19 16:22:16
date last changed
2018-09-23 03:39:47
@article{4f2db317-ae5c-4a36-a172-13348bc0bfc9,
  abstract     = {Several serum and urine biochemical markers of bone resorption and formation have been developed. Biochemical bone markers have been used as intermediate end-points in all major studies of anti-osteoporotic therapies. Bone resorption markers, in particular, may add an independent, predictive value to the assessment of bone loss and fracture risk. There are also potential advantages in monitoring anti-osteoporotic treatment in the short-term in addition to bone densitometry, to rapidly identify non-responders to therapy, or non-compliance. Despite these recent advances, until now bone markers have simply been very useful research tools, with their clinical utility being limited by intra-individual and diurnal variability. However, the probability of the true bone mineral density response to hormone replacement therapy for the individual patient may be predicted using algorithms based on a spectrum of cut-off bone marker levels with varying false positive and negative rates. Thus, the transition of biochemical bone markers into everyday clinical practice may be rapidly approaching.},
  author       = {Ebeling, P and Åkesson, Kristina},
  issn         = {1532-1770},
  keyword      = {biochemical bone markers,fracture risk,therapy,bone density,non-responders},
  language     = {eng},
  number       = {3},
  pages        = {385--400},
  publisher    = {Baillière Tindall},
  series       = {Baillière's Best Practice & Research: Clinical Rheumatology},
  title        = {Role of biochemical markers in the management of osteoporosis},
  url          = {http://dx.doi.org/10.1053/berh.2001.0156},
  volume       = {15},
  year         = {2001},
}